USP7–PKM2 Axis Directs Macrophage Polarization in Pancreatitis

Study Background and Research Question

Severe acute pancreatitis (SAP) remains a life-threatening inflammatory condition characterized by extensive immune dysregulation and a high risk of multi-organ failure. Despite advances in critical care, there are no targeted therapies proven to interrupt the inflammatory cascade driving SAP progression. Macrophages, particularly their polarization states, are central to the pathogenesis of SAP: M1-type macrophages exacerbate tissue injury via pro-inflammatory cytokine production, while M2-type macrophages foster resolution and tissue repair. Recent studies have suggested that these phenotypic shifts are tightly linked to underlying metabolic states, particularly the balance between glycolysis and oxidative phosphorylation.

In this context, the reference paper addresses a critical knowledge gap: How does ubiquitin-specific protease 7 (USP7), a key regulator of protein ubiquitination, influence macrophage polarization through metabolic pathways—specifically via modulation of pyruvate kinase M2 (PKM2), a glycolytic enzyme known for its dual roles in metabolism and gene regulation?

Key Innovation from the Reference Study

The core innovation presented by Yao Wu and colleagues lies in their identification of a USP7–PKM2 regulatory axis that orchestrates macrophage phenotypic fate in SAP. By demonstrating that USP7 promotes M1-type polarization through PKM2-mediated metabolic reprogramming, the study provides a mechanistic bridge between post-translational protein modification and metabolic control of immune function. Notably, the authors show that USP7 knockdown not only reduces pro-inflammatory signaling but also shifts macrophages toward the anti-inflammatory M2 phenotype, with functional consequences for disease severity. The study further establishes that these effects are dependent on PKM2 activity, as pharmacological PKM2 inhibition abrogates the protective impact of USP7 knockdown.

Methods and Experimental Design Insights

The investigators employed a comprehensive in vivo and in vitro strategy to dissect the USP7–PKM2 axis:

• Animal Model: SAP was induced in mice to recapitulate the inflammatory environment of human disease. USP7 expression was evaluated in pancreatic macrophages from these animals.
• Phenotypic Characterization: Macrophage subtypes were identified by immunofluorescence, flow cytometry, and Western blotting, focusing on key M1 and M2 markers.
• Inflammatory Readouts: Serum amylase and lipase activities, along with pro-inflammatory cytokine levels, provided quantitative metrics for disease severity.
• Metabolic Profiling: Seahorse assays measured extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) to assess glycolytic and oxidative metabolism.
• Molecular Mechanisms: Co-immunoprecipitation and ubiquitinated immunoprecipitation assays delineated the interaction and post-translational regulation between USP7 and PKM2.
• Pharmacological Validation: A selective PKM2 inhibitor was used in vivo to determine the functional relevance of PKM2 in mediating the effects of USP7 knockdown.

Core Findings and Why They Matter

Several key findings emerged from the study:

• USP7 is upregulated in SAP macrophages. In SAP-induced mice, pancreatic macrophages showed increased USP7 expression, implicating this protease in disease pathogenesis.
• USP7 knockdown reduces inflammation and disease severity. Genetic silencing of USP7 resulted in lower serum amylase and lipase, decreased pro-inflammatory cytokines, and histological improvement in pancreatic tissue, according to the reference study.
• Macrophage polarization shifts from M1 to M2 with USP7 inhibition. Both in vivo and in vitro, suppression of USP7 led to reduced M1 (pro-inflammatory) and increased M2 (anti-inflammatory) macrophage markers, supporting a role for USP7 in immune cell fate determination.
• Metabolic reprogramming underlies macrophage phenotype control. M1-polarized macrophages exhibited increased glycolysis and reduced oxidative phosphorylation, whereas USP7 knockdown restored metabolic balance, favoring OXPHOS—consistent with M2 polarization.
• USP7 modulates PKM2 stability and function. Molecular analyses showed that USP7 directly interacts with and deubiquitinates PKM2, promoting its phosphorylation and nuclear translocation. This modification enhances PKM2’s role in driving glycolytic flux and pro-inflammatory gene expression.
• PKM2 activity is essential for USP7-driven effects. Administration of a PKM2 inhibitor in SAP mice partially reversed the benefits of USP7 knockdown, confirming that USP7’s immunometabolic effects are PKM2-dependent.

Together, these results establish a functional axis wherein USP7 fosters pro-inflammatory macrophage polarization via stabilization and nuclear activity of PKM2. By disrupting this axis, the study points to new opportunities for targeting metabolic pathways in immune-mediated diseases.

Comparison with Existing Internal Articles

Several prior resources have explored the role of PKM2 inhibitors in cancer and immunometabolic modulation. For example, the article "PKM2 Inhibitor (Compound 3k): Selective Glycolytic Modulation" highlights the efficacy of PKM2 inhibitor (compound 3k) in disrupting aerobic glycolysis in tumor cells and modulating immune cell metabolism. Similarly, "USP7–PKM2 Axis Regulates Macrophage Polarization in SAP" provides an overview of the mechanistic interplay between USP7 and PKM2 in inflammatory settings, aligning closely with the findings of the reference study.

What distinguishes the current reference is its rigorous demonstration of causality in the USP7–PKM2 interaction and the explicit use of PKM2 inhibition to dissect pathway dependencies in vivo. While internal articles discuss the translational potential of PKM2 inhibitors as metabolic and immunomodulatory tools, the new study provides direct, disease-relevant evidence for this approach in SAP, a context previously underexplored.

Limitations and Transferability

Despite its strengths, the study has certain limitations:

• Model specificity: Findings are based on murine SAP models, which—though informative—may not fully recapitulate human disease biology.
• Pharmacological specificity: The PKM2 inhibitor used in the study, while selective, may have off-target effects not fully characterized in this setting.
• Translational boundaries: While modulation of the USP7–PKM2 axis shows promise for acute inflammation, further studies are necessary to assess long-term outcomes, optimal dosing strategies, and safety in humans.

Nonetheless, the demonstration of metabolic control over macrophage polarization via a defined enzymatic axis suggests broader applicability in other inflammatory and immune-mediated conditions, pending further validation.

Protocol Parameters

• USP7 knockdown: Lentiviral shRNA transduction in murine macrophages; confirm knockdown by Western blot before functional assays.
• SAP model induction: Use established caerulein plus LPS protocol in mice; monitor serum amylase/lipase as disease markers.
• Macrophage polarization assessment: Apply F4/80, CD86 (M1), and CD206 (M2) immunofluorescence/flow cytometry for phenotyping.
• Metabolic profiling: Perform Seahorse ECAR/OCR assays to distinguish glycolytic and oxidative phenotypes following genetic or pharmacological modulation.
• PKM2 inhibition: Administer PKM2 inhibitor (compound 3k) at doses validated in literature (e.g., 5 mg/kg oral gavage in mice every other day for 31 days when modeling tumor xenografts; SAP-specific protocols may require adaptation).

Research Support Resources

Researchers seeking to further investigate PKM2’s role in immunometabolism or replicate the USP7–PKM2 axis disruption in their models can utilize PKM2 inhibitor (compound 3k) (SKU B8217), a potent and selective tool for studying glycolytic modulation in both tumor and immune cell systems. According to the product information, compound 3k exhibits robust selectivity and in vivo applicability, making it suitable for translational workflows targeting PKM2-overexpressing cells.